Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 360 citing articles:

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane Cordeiro Veiga, João Antônio Gonçalves Garreta Prats, Danielle Leão Cordeiro de Farias, et al.
BMJ (2021), pp. n84-n84
Open Access | Times Cited: 382
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, et al.
JAMA (2021) Vol. 325, Iss. 3, pp. 254-254
Open Access | Times Cited: 335
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher Butler, Jienchi Dorward, Ly‐Mee Yu, et al.
The Lancet (2021) Vol. 397, Iss. 10279, pp. 1063-1074
Open Access | Times Cited: 272
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 5, pp. 601-621
Open Access | Times Cited: 250
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Bacterial Coinfections in Coronavirus Disease 2019
Lars F. Westblade, Matthew S. Simon, Michael J. Satlin
Trends in Microbiology (2021) Vol. 29, Iss. 10, pp. 930-941
Open Access | Times Cited: 187
How COVID-19 has fundamentally changed clinical research in global health
Jay Park, Robin Mogg, Gerald E. Smith, et al.
The Lancet Global Health (2021) Vol. 9, Iss. 5, pp. e711-e720
Open Access | Times Cited: 175
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 150
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic
Gregory A. Roth, Sophia Emmons‐Bell, Heather M. Alger, et al.
JAMA Network Open (2021) Vol. 4, Iss. 5, pp. e218828-e218828
Open Access | Times Cited: 134
COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Larissa E. van Eijk, Mathijs Binkhorst, Arno R. Bourgonje, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 307-331
Open Access | Times Cited: 122
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
Parastoo Tarighi, S. Eftekhari, Milad Chizari, et al.
European Journal of Pharmacology (2021) Vol. 895, pp. 173890-173890
Open Access | Times Cited: 116
Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2
Ashuai Du, Rong Zheng, Cyrollah Disoma, et al.
International Journal of Biological Macromolecules (2021) Vol. 176, pp. 1-12
Open Access | Times Cited: 106
Combating Oxidative Stress and Inflammation in COVID‐19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives
Duried Alwazeer, Franky Fuh-Ching Liu, Xiao Yu Wu, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 102
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
Charan Thej Reddy Vegivinti, Kirk W. Evanson, Hannah Lyons, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 93
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development
M Sreepadmanabh, Amit Kumar Sahu, Ajit Chande
Journal of Biosciences (2020) Vol. 45, Iss. 1
Open Access | Times Cited: 106
Self-medication practices to prevent or manage COVID-19: A systematic review
Alvaro Quincho-Lopez, Christeam A. Benites-Ibarra, Maryori M. Hilario-Gómez, et al.
PLoS ONE (2021) Vol. 16, Iss. 11, pp. e0259317-e0259317
Open Access | Times Cited: 95
Azithromycin for severe COVID-19
Catherine E. Oldenburg, Thuy Doan
The Lancet (2020) Vol. 396, Iss. 10256, pp. 936-937
Open Access | Times Cited: 92
A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment
Ramiro Picoli Nippes, Paula Derksen Macruz, Gabriela Nascimento da Silva, et al.
Process Safety and Environmental Protection (2021) Vol. 152, pp. 568-582
Open Access | Times Cited: 89
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Hui Lin, Sanda Cho, Veeraraghavan Meyyur Aravamudan, et al.
Infection (2021) Vol. 49, Iss. 3, pp. 401-410
Open Access | Times Cited: 87
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Omkar Indari, Shweta Jakhmola, E. Manivannan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 86
NSAIDs and COVID-19: A Systematic Review and Meta-analysis
Nicholas Moore, Pauline Bosco‐Lévy, Nicolas H. Thurin, et al.
Drug Safety (2021) Vol. 44, Iss. 9, pp. 929-938
Open Access | Times Cited: 80
Page 1 - Next Page

Scroll to top